Autolus Therapeutics plc
NASDAQ:AUTLBiotechnology
+$0.01 today
- Market cap
- $282.13M
- Beta
- 2.01
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$1.09
Volume 2.56M
Average 1.60M
AUTL EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Autolus Therapeutics plcNASDAQ: AUTL
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$56.94M, compared with -$55.52M a year earlier. Trailing-twelve-month EBITDA was -$230.8M.
Context
- EBITDA amounted to 331.2% of revenue in FY2025, down 1971.9 pp from a year earlier.
- EBITDA grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 6 analysts of -$147.19M (+41.2%) for the fiscal year ending Dec 2026, a step up from the -7.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$56.94M+13.7% QoQ
- Last fiscal yearDec 2025
- -$250.26M-7.4% YoY
- LTMMar 2026
- -$230.8M+3.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -2.6% | -7.4% | -4.8 pp |
| 1 year | -7.4% | +41.2% | +48.6 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (250.26M) USD
- Year-over-year change
- -7.4%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (250.26M) | -7.4% |
| FY2024 | 2024-12-31 | (233.07M) | -48.7% |
| FY2023 | 2023-12-31 | (156.77M) | -18.5% |
| FY2022 | 2022-12-31 | (132.24M) | +0.2% |
| FY2021 | 2021-12-31 | (132.48M) | — |
EBITDA vs competitors
How AUTL compares with its peers on the latest reported figures
- AUTL's LTM Mar 2026 EBITDA of -$230.8M is the 9th highest of the 10 companies compared; the peer median is -$89.9M.
- Its year-over-year change of +3.4% is the 6th highest of 10, against a peer median of +4.6%.
- EBITDA amounts to 249.3% of revenue for AUTL, versus a peer median of 89.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $99.55M | +154.3% | — | 7.3% | |
| LTM Mar 2026 | -$5.48M | +4.6% | — | 23.7% | |
| LTM Mar 2026 | -$40.42M | -143.9% | — | 89.7% | |
| LTM Mar 2026 | -$51.11M | -57.3% | — | 75.1% | |
| LTM Mar 2026 | -$89.9M | -1211.1% | — | — | |
| LTM Mar 2026 | -$111.97M | +23.4% | — | 999.5% | |
| LTM Mar 2026 | -$117.42M | +23.4% | — | 1859.1% | |
| LTM Mar 2026 | -$160.41M | +32.7% | — | — | |
| LTM Mar 2026 | -$230.8M | +3.4% | — | 249.3% | |
| LTM Mar 2026 | -$238.99M | -27.7% | — | 770932.3% | |
| Peer median (excluding AUTL) | -$89.9M | +4.6% | — | 89.7% | |
Competitors are the stored peer set for AUTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.51M | 6.19M | 1.7M | 10.12M | 75.56M |
| Cost of Revenue | 0 | 0 | 0 | 141.02M | 96.59M |
| Gross Profit | 1.51M | 6.19M | 1.7M | (130.9M) | (21.03M) |
| Gross Margin | 100.0% | 100.0% | 100.0% | -1293.5% | -27.8% |
| Research & Development | 110.84M | 117.35M | 130.48M | 158.14M | 128.59M |
| Selling, General & Admin | 31.87M | 31.9M | 46.75M | 0 | 131.82M |
| Operating Expenses | 141.88M | 149.09M | 181.4M | 110.53M | 260.41M |
| Depreciation & Amortization | 8.46M | 7.42M | 6.57M | 7.72M | 9.84M |
| EBITDA | (132.48M) | (132.24M) | (156.77M) | (233.07M) | (250.26M) |
| EBITDA Margin | -8790.6% | -2135.0% | -9232.6% | -2303.1% | -331.2% |
| Operating Income | (140.37M) | (142.89M) | (179.7M) | (241.43M) | (281.44M) |
| Operating Margin | -9314.8% | -2307.0% | -10583.1% | -2385.6% | -372.4% |
| Interest Income | 262K | 1.71M | 13.51M | 32.36M | 19.02M |
| Interest Expense | 1.11M | 8.91M | 45.07M | 9.29M | 36.76M |
| Other Income / Expenses | (1.66M) | (5.67M) | (28.7M) | 22.29M | (15.41M) |
| Income Before Tax | (142.04M) | (148.57M) | (208.4M) | (219.13M) | (296.85M) |
| Pre-Tax Margin | -9425.2% | -2398.6% | -12273.4% | -2165.4% | -392.8% |
| Income Tax Expense | 58K | 272K | (19K) | 1.53M | (8.65M) |
| Net Income | (142.1M) | (148.84M) | (208.38M) | (220.66M) | (288.2M) |
| Net Margin | -9429.1% | -2403.0% | -12272.3% | -2180.5% | -381.4% |
| EPS (Basic) | (1.97) | (1.57) | (1.20) | (0.87) | (1.08) |
| EPS (Diluted) | (1.97) | (1.57) | (1.20) | (0.87) | (1.08) |
| Weighted Avg Shares | 72.08M | 94.99M | 173.94M | 255.16M | 266.14M |
| Weighted Avg Shares (Diluted) | 72.08M | 94.99M | 173.94M | 255.16M | 266.14M |
Autolus Therapeutics plc
NASDAQ:AUTL
Intrinsic Alpha fair value
Locked
Current Price
$1.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.